A nutritional supplement for pets
By using lychee polyphenols and astaxanthin as the core of nutritional supplements, combined with a variety of natural extracts, the problems of toxic side effects and insignificant efficacy of existing drugs have been solved, achieving a safe and effective treatment for myocardial injury in pets.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHANDONG SINDER TECH CO LTD
- Filing Date
- 2024-07-10
- Publication Date
- 2026-08-04
AI Technical Summary
Existing drugs used to treat myocardial injury in pets have problems such as toxic side effects or insignificant efficacy, and early myocardial injury is easily overlooked, leading to the progression of the disease to the middle and late stages.
This nutritional supplement uses lychee polyphenols and astaxanthin as its core components, supplemented with garlic extract, ginkgo leaf extract, folic acid, organic germanium, flaxseed extract, and chicken breast powder, to significantly improve myocardial damage through synergistic effects and provide multiple protective mechanisms.
It significantly reduces myocardial damage, inhibits inflammatory responses, reduces cell apoptosis, and improves myocardial cell function. Moreover, its ingredients are safe and have no toxic side effects, making it suitable for long-term use.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of medical technology, and in particular relates to a nutritional supplement for pets. Background Technology
[0002] As people's living standards improve, more and more people are keeping pets, and many consider cats and dogs family members, providing them with similar diets and living conditions as humans. This trend has led to a growing problem of obesity in pets, especially cats and dogs, and a significant increase in the incidence of myocardial damage. Studies have shown that in some large cities, the incidence of cardiovascular disease in cats and dogs has reached approximately 13%. Furthermore, the aging of pets is intensifying year by year, further increasing the risk of cardiovascular disease. Heart damage poses a serious threat to the health of pets, and can even endanger their lives.
[0003] Currently, the main methods used clinically to treat myocardial injury in pets include single biological agents, chemical drugs, or traditional Chinese medicine preparations. Long-term use of chemical drugs may lead to significant toxic side effects, which are detrimental to the overall health of pets; while traditional Chinese medicine, due to its slow onset of action and unclear mechanism of action, often fails to achieve the expected therapeutic effect.
[0004] Early-stage myocardial injury in pets often presents no obvious symptoms and is easily overlooked. By the time symptoms become apparent, the condition has typically progressed to a middle or late stage. Therefore, effective treatment and management of myocardial injury in pets are crucial. Against this backdrop, the development of a rapidly effective drug with no toxic side effects is urgently needed. Summary of the Invention
[0005] The purpose of this invention is to provide a nutritional supplement for pets.
[0006] To achieve the above objectives, the present invention provides the following technical solution: First, the present invention provides a nutritional supplement for pets, the nutritional supplement comprising a core component and auxiliary components, wherein the core component is composed of lychee polyphenols and astaxanthin.
[0007] Preferably, the core component accounts for 20% of the weight of the nutritional supplement, and the weight ratio of litchi polyphenols and astaxanthin in the core component is 1:1.
[0008] Preferably, the auxiliary components consist of garlic extract, ginkgo leaf extract, folic acid, organic germanium, flaxseed extract, chicken breast powder, and anhydrous glucose.
[0009] Preferably, the nutritional supplement is composed of the following components: 100 parts of lychee polyphenols, 100 parts of astaxanthin, 1-5 parts of garlic extract, 25-35 parts of ginkgo leaf extract, 0.2-0.3 parts of folic acid, 7-12 parts of organic germanium, 5-8 parts of flaxseed extract, 400 parts of chicken breast powder, and 339.7-361.8 parts of anhydrous glucose.
[0010] Preferably, the nutritional supplement is composed of the following components by weight: 100 parts lychee polyphenols, 100 parts astaxanthin, 5 parts garlic extract, 35 parts ginkgo leaf extract, 0.3 parts folic acid, 12 parts organic germanium, 8 parts flaxseed extract, 400 parts chicken breast powder, and 339.7 parts anhydrous glucose.
[0011] Preferably, the nutritional supplement is prepared according to the following method: (1) Material selection: Weigh and prepare the raw materials according to the components and proportions in the above formula; (2) Sieving: Pass the raw materials from step (1) through a 60-mesh sieve for later use; (3) Place the sieved raw materials in a three-dimensional mixer and mix for 15 minutes to ensure that they are fully mixed and homogeneous, thus obtaining a nutritional supplement for pets.
[0012] Secondly, the present invention provides the use of a composition in the preparation of a drug for treating myocardial injury, the drug being composed of the composition and a pharmaceutically acceptable carrier, wherein the composition comprises 20% of the drug and the composition is composed of litchi polyphenols and astaxanthin.
[0013] Preferably, the weight ratio of litchi polyphenols to astaxanthin in the composition is 1:1.
[0014] Secondly, the present invention provides a composition for treating myocardial injury, the composition comprising litchi polyphenols and astaxanthin, wherein the weight ratio of litchi polyphenols to astaxanthin in the composition is 1:1.
[0015] Secondly, the present invention provides the application of a composition in the preparation of an inhibitor for inhibiting lipopolysaccharide-induced myocardial cell damage, the composition being composed of litchi polyphenols and astaxanthin, wherein the concentration of litchi polyphenols in the inhibitor is 100 μg / mL and the concentration of astaxanthin in the inhibitor is 100 μg / mL.
[0016] Secondly, the present invention provides an inhibitor for inhibiting myocardial cell damage caused by lipopolysaccharide, the inhibitor being composed of litchi polysaccharide, astaxanthin and a pharmaceutically acceptable carrier, wherein the concentration of litchi polysaccharide in the inhibitor is 100 μg / mL and the concentration of astaxanthin in the inhibitor is 100 μg / mL.
[0017] The beneficial effects of this invention are as follows: 1. Significant Synergistic Effect: The core components of this invention, litchi polyphenols and astaxanthin, possess strong antioxidant and anti-inflammatory effects, respectively. However, when used in combination, their therapeutic effect is significantly better than when used alone. This synergistic effect can more effectively reduce myocardial damage, inhibit inflammatory responses, reduce cell apoptosis, and improve cardiomyocyte function.
[0018] 2. Multiple protective mechanisms: Supporting components such as garlic extract, ginkgo leaf extract, folic acid, organic germanium, and flaxseed extract all possess excellent antioxidant, anti-inflammatory, and immunomodulatory effects, further enhancing the therapeutic efficacy of the core component. Chicken breast powder and anhydrous glucose not only improve the product's palatability and nutritional value but may also enhance the overall therapeutic effect by improving drug bioavailability.
[0019] 3. Safety and no toxic side effects: The ingredients used in this invention are all natural extracts and food-grade materials, which are safe and non-toxic. Long-term use will not produce significant toxic side effects, making it suitable for long-term feeding of pets and ensuring their heart health.
[0020] In summary, this invention provides an effective nutritional supplement for pets that significantly improves the therapeutic effect of myocardial injury through the synergistic action of the core components, lychee polyphenols and astaxanthin, and the multiple protective mechanisms of the auxiliary components. Experimental results show that this supplement has significant advantages in reducing cell apoptosis rate, inflammatory factor levels, and myocardial injury markers. This supplement is safe and non-toxic, suitable for long-term use, and has broad application prospects. Detailed Implementation
[0021] Example 1 Raw materials for preparation: A pet nutritional supplement 1 consists of core components and auxiliary components. The core components are 100 parts of lychee polyphenols and 100 parts of astaxanthin. The auxiliary components are 5 parts of garlic extract, 35 parts of ginkgo leaf extract, 0.3 parts of folic acid, 12 parts of organic germanium, 8 parts of flaxseed extract, 400 parts of chicken breast powder, and 339.7 parts of anhydrous glucose. The garlic extract, ginkgo leaf extract, and flaxseed extract were purchased from Sichuan Hengruitongda Company, and the chicken breast powder was purchased from Tianjin Chunfa Biotechnology Company.
[0022] Preparation method: (1) Material selection: Weigh and prepare the raw materials according to the components and proportions in the above formula; (2) Sieving: Pass the raw materials from step (1) through a 60-mesh sieve for later use; (3) Place the sieved raw materials in a three-dimensional mixer and mix for 15 minutes to ensure that they are fully mixed and homogeneous, thus obtaining a nutritional supplement for pets.
[0023] Example 2 Raw materials for preparation: A pet nutritional supplement 2 is composed of core components and auxiliary components. The core components are 100 parts of lychee polyphenols and 100 parts of astaxanthin. The auxiliary components are 1 part of garlic extract, 25 parts of ginkgo leaf extract, 0.2 parts of folic acid, 7 parts of organic germanium, 5 parts of flaxseed extract, 400 parts of chicken breast powder, and 361.8 parts of anhydrous glucose.
[0024] Preparation method: (1) Material selection: Weigh and prepare the raw materials according to the components and proportions in the above formula; (2) Sieving: Pass the raw materials from step (1) through a 60-mesh sieve for later use; (3) Place the sieved raw materials in a three-dimensional mixer and mix for 15 minutes to ensure that they are fully mixed and homogeneous, thus obtaining a nutritional supplement for pets.
[0025] Comparative Example 1 Similar products sold on the market for relieving myocardial damage. The main ingredients of these products are coenzyme Q10, L-carnitine, tea polyphenols, fructooligosaccharides, isomaltooligosaccharides, taurine, soybean extract, yam extract, garlic extract, black sesame powder, black fungus polysaccharides, selenium-enriched yeast, trimethylglycine, amino acid chelated magnesium, vitamin C, vitamin E, vitamin B1, vitamin B2, vitamin B6, and vitamin B12.
[0026] Comparative Example 2 A pet nutritional supplement 3 is composed of the following components: 200 parts astaxanthin, 5 parts garlic extract, 35 parts ginkgo leaf extract, 0.3 parts folic acid, 12 parts organic germanium, 8 parts flaxseed extract, 400 parts chicken breast powder, and 339.7 parts anhydrous glucose.
[0027] The preparation method is the same as in Example 1.
[0028] Comparative Example 3 A pet nutritional supplement 4 is composed of the following components: 200 parts of lychee polyphenols, 5 parts of garlic extract, 35 parts of ginkgo leaf extract, 0.3 parts of folic acid, 12 parts of organic germanium, 8 parts of flaxseed extract, 400 parts of chicken breast powder, and 339.7 parts of anhydrous glucose.
[0029] The preparation method is the same as in Example 1.
[0030] Comparative Example 4 A pet nutritional supplement 5 is composed of the following components: 200 parts coenzyme Q10, 5 parts garlic extract, 35 parts ginkgo leaf extract, 0.3 parts folic acid, 12 parts organic germanium, 8 parts flaxseed extract, 400 parts chicken breast powder, and 339.7 parts anhydrous glucose.
[0031] The preparation method is the same as in Example 1.
[0032] Experimental Example 1 The effects of the core ingredients in the formula were tested through cell experiments. (1) Rat H9C2 cardiomyocytes were selected and randomly divided into blank group, lipopolysaccharide control group, lipopolysaccharide + litchi polyphenol group, lipopolysaccharide + astaxanthin group, and LPS + litchi polyphenol + astaxanthin group. (2) The blank group cells were cultured normally. The lipopolysaccharide control group was treated with 1 μg / mL lipopolysaccharide for 24 h. The lipopolysaccharide + litchi polyphenol group was treated with 1 μg / mL lipopolysaccharide and 200 μg / mL litchi polyphenol for 24 h. The lipopolysaccharide + astaxanthin group was treated with 1 μg / mL lipopolysaccharide and 200 μg / mL astaxanthin for 24 h. The lipopolysaccharide + litchi polyphenol + astaxanthin group was treated with 1 μg / mL lipopolysaccharide, 100 μg / mL litchi polyphenol and 100 μg / mL astaxanthin for 24 h.
[0033] (3) The apoptosis of H9C2 cells was detected by TUNEL assay, and the levels of TNF-α and IL-1β in cardiomyocytes were detected by ELISA kit. The experimental results are shown in Table 1: Table 1. Results of cell experiment detection
[0034] As can be seen from Table 1, regarding the apoptosis rate: Lipopolysaccharide significantly increased the apoptosis rate (blank group: 2.55% vs lipopolysaccharide control group: 32.71%). Both litchi polyphenols and astaxanthin can reduce the apoptosis rate induced by lipopolysaccharide when used alone, but litchi polyphenols have a more significant effect (15.22% vs 23.12%). When litchi polyphenols and astaxanthin were used in combination, the cell apoptosis rate was reduced to the lowest level (6.77%), close to the level of the blank group, showing a significant synergistic effect.
[0035] Regarding TNF-α levels: Lipopolysaccharide significantly increased TNF-α levels (blank group: 130.55 pg / mL vs lipopolysaccharide control group: 864.37 pg / mL); Both litchi polyphenols and astaxanthin can reduce TNF-α levels when used alone, with litchi polyphenols showing a better effect (368.47 pg / mL vs 524.65 pg / mL). When used in combination, TNF-α levels further decreased to 201.74 pg / mL, demonstrating a synergistic anti-inflammatory effect.
[0036] For IL-1β levels: Lipopolysaccharide significantly increased IL-1β levels (blank group: 196.85 pg / mL vs lipopolysaccharide control group: 1123.41 pg / mL). Both litchi polyphenols and astaxanthin can reduce IL-1β levels when used alone, with litchi polyphenols showing a more significant effect (577.69 pg / mL vs 768.35 pg / mL). When used in combination, IL-1β levels decreased to 307.64 pg / mL, demonstrating a significant synergistic anti-inflammatory effect.
[0037] Comprehensive analysis revealed that litchi polyphenols and astaxanthin exhibited synergistic effects in reducing lipopolysaccharide-induced apoptosis rates and the levels of inflammatory factors (TNF-α and IL-1β). While either litchi polyphenols or astaxanthin alone showed significant effects, the combined use yielded the best results, significantly improving apoptosis and inflammatory responses. This suggests that the combined application of litchi polyphenols and astaxanthin has potential advantages in treating heart disease-related inflammation and cellular damage.
[0038] Experimental Example 2 (1) 40 normal SPF rats were selected, 5 of which were randomly selected as normal control group, and the remaining 35 rats were constructed according to the construction steps of myocardial ischemia-reperfusion myocardial injury model. The myocardial injury rats were divided into 7 groups: Example 1 group, Example 2 group, Comparative Example 1 group, Comparative Example 2 group, Comparative Example 3 group, Comparative Example 4 group, and myocardial injury group. (2) After grouping, blood samples were collected for testing of cTnT, saa, and bnp. cTnT is cardiac troponin T, present in the myocardium. When the myocardium is damaged, troponin T can be released into the blood, increasing its concentration. The normal reference range for veterinary hospitals is 0-0.9. saa, or serum amyloid A, is a sensitive indicator reflecting early inflammation in infectious diseases and is a test for inflammatory infections. The normal reference range is 0-2. bnp is a brain natriuretic peptide secreted by heart cells. Increased cardiac contractile pressure leads to increased bnp secretion. Therefore, testing a cat's bnp level can detect heart problems such as cardiomyopathy, palpitations, or other cardiovascular diseases. If the test result shows a positive bnp result in a cat, it indicates a cardiac abnormality requiring timely diagnosis and treatment.
[0039] (3) Each group was fed the same diet and water. Specifically, Example 1 was fed 10g of the nutritional supplement prepared in Example 1, Example 2 was fed 10g of the nutritional supplement prepared in Example 2, Comparative Example 1 was fed the nutritional supplement prepared in Comparative Example 1, Comparative Example 2 was fed 10g of the nutritional supplement prepared in Comparative Example 2, Comparative Example 3 was fed 10g of the nutritional supplement prepared in Comparative Example 3, and Comparative Example 4 was fed 10g of the nutritional supplement prepared in Comparative Example 4. During the period, they had free access to food and water.
[0040] (4) After feeding for 1 month, blood samples were collected to detect cTnT, saa, and bnp. The results are shown in Table 2.
[0041] Table 2 Differences in myocardial injury indicators before and after treatment
[0042] The experimental results show that Comparative Example 1 of the existing formula performed the worst in treating myocardial injury, indicating that its components and proportions are ineffective in alleviating myocardial damage. Comparative Example 4, which uses Coenzyme Q as its core component, showed some improvement, but the results were still unsatisfactory, demonstrating that Coenzyme Q has limited ability to repair myocardial damage when used alone.
[0043] Consistent with the results of cell experiments, Comparative Example 3, using litchi polyphenols alone, showed better therapeutic effects than Comparative Example 2, using astaxanthin alone. This indicates that litchi polyphenols have a stronger effect in protecting cardiomyocytes, reducing inflammation, and providing antioxidant benefits. However, the combined effect of either ingredient alone was not as good as that of using either ingredient in combination.
[0044] When litchi polyphenols and astaxanthin were used in combination, Examples 1 and 2 showed significantly better results than all comparative examples (1-4), indicating a significant synergistic effect between litchi polyphenols and astaxanthin. Specifically, the combination of litchi polyphenols and astaxanthin more effectively reduced myocardial damage, inhibited inflammatory responses, reduced apoptosis, and improved cardiomyocyte function.
[0045] Further analysis showed that Example 1 was more effective than Example 2, indicating that the auxiliary component in Example 1 could further enhance the synergistic effect of litchi polyphenols and astaxanthin, possibly by providing additional antioxidant protection or improving drug bioavailability, thereby improving the overall therapeutic effect.
[0046] Example 3 The nutritional supplements from Example 1 and Comparative Example 1 were used in a clinical trial at a university animal hospital in Wuhan, Hubei Province. A total of six cats with myocardial injury were used. The cats were randomly divided into two groups of three each. Blood samples were collected before the trial to measure cTnT, SAA, and BNP. All animals were kept in the same living and feeding conditions except for the addition of the experimental product. Example 1 cats received an additional nutritional supplement prepared in Example 1, and Comparative Example 1 cats received an additional nutritional supplement prepared in Comparative Example 1. Each cat was fed 10g of the nutritional supplement daily for one month. Blood samples were collected after the trial to measure cTnT, SAA, and BNP. The results are shown in Table 3 below. Table 3 Blood Test Indicators in Pet Hospital Cases
[0047] The experimental results show that the nutritional supplement used in Example 1 was significantly more effective than that used in Comparative Example 1, which is consistent with the results of our rat animal experiments. This indicates that the nutritional supplement used in Example 1 was significantly effective in alleviating myocardial injury in cats, while the commercially available nutritional supplement in Comparative Example 1 could not effectively alleviate myocardial injury.
[0048] In summary, the experimental results clearly demonstrate that coenzyme Q10, litchi polyphenols, or astaxanthin alone are all effective in treating myocardial injury, but litchi polyphenols are more effective than astaxanthin, while coenzyme Q10 alone is the least effective. However, the combined use of litchi polyphenols and astaxanthin significantly enhances the therapeutic effect, demonstrating a strong synergistic effect. The formulation in Example 1, due to its specific auxiliary components, exhibits the best therapeutic effect, further demonstrating the importance of optimized formulation design in the treatment of myocardial injury.
Claims
1. The use of a composition in the preparation of a medicament for treating myocardial injury, characterized in that, The drug comprises a composition and a pharmaceutically acceptable carrier, wherein the composition comprises 20% of the drug and consists of litchi polyphenols and astaxanthin. The weight ratio of litchi polyphenols to astaxanthin in the composition is 1:
1.
2. A composition for treating myocardial injury, characterized in that, The composition consists of litchi polyphenols and astaxanthin, wherein the weight ratio of litchi polyphenols to astaxanthin in the composition is 1:1.